MarkEMcGovernMD

PubMed

• 2 citations
  Effects of Extended-Release Niacin on Quartile Lp-PLA2 Levels and Clinical Outcomes in Statin-treated Patients with Established Cardiovascular Disease and Low Baseline...
  Radmila Lyubarova, John J. Albers, Santica M. Marcovina, Yao Yao, Ruth McBride, Alexandru Topliceanu, Todd Anderson, Jerome L. Fleg, Patrice Desvigne-Nickens, Moti L. ...> ;Journal of Cardiovascular Pharmacology and Therapeutics. 2019 May 26
• 4 citations
  Cardiovascular outcomes during extended follow-up of the AIM-HIGH trial cohort.
  Jeffrey L. Probstfield, William E. Boden, Todd Anderson, Kelley R. Branch, Moti L. Kashyap, Jerome L. Fleg, Patrice Desvigne-Nickens, Ruth McBride, Mark E. McGovern, A...> ;Journal of Clinical Lipidology. 2018 Nov 1
• 60 citations
  Understanding the Association between Stunting and Child Development in Low- and Middle-Income Countries: Next Steps for Research and Intervention
  Jessica M. Perkins, Rockli Kim, Aditi Krishna, Mark E. McGovern, Victor M. Aguayo, S.V. Subramanian> ;Social Science & Medicine. 2017 Nov 1
• 94 citations
  A review of the evidence linking child stunting to economic outcomes.
  Mark E. McGovern, Aditi Krishna, Victor M. Aguayo, S.V. Subramanian> ;International Journal of Epidemiology. 2017 Aug 1
• 20 citations
  Do gifts increase consent to home-based HIV testing? A difference-in-differences study in rural KwaZulu-Natal, South Africa.
  Mark E. McGovern, Kobus Herbst, Frank Tanser, Tinofa Mutevedzi, David Canning, Dickman Gareta, Deenan Pillay, Till Bärnighausen> ;International Journal of Epidemiology. 2016 Dec 1
• 10 citations
  Adjusting HIV prevalence estimates for non-participation: an application to demographic surveillance
  Mark E. McGovern, G. Marra, Rosalba Radice, David Canning, Marie-Louise Newell, Till Bärnighausen> ;Journal of the International AIDS Society. 2015 Nov 26
• 11 citations
  On the assumption of bivariate normality in selection models: a copula approach applied to estimating HIV prevalence
  Mark E. McGovern, Till Bärnighausen, Giampiero Marra, Rosalba Radice> ;Epidemiology. 2015 Mar 1
• 11 citations
  Using interviewer random effects to remove selection bias from HIV prevalence estimates
  Mark E. McGovern, Till Bärnighausen, Joshua A. Salomon, David Canning> ;BMC Medical Research Methodology. 2015 Feb 5
• 10 citations
  Optimal pharmacotherapy to combat the atherogenic lipid triad.
  M. John Chapman, J. S. Redfern, Mark E. McGovern, Philippe Giral> ;Current Opinion in Cardiology. 2011 Sep 1
• 139 citations
  Niacin and fibrates in atherogenic dyslipidemia: Pharmacotherapy to reduce cardiovascular risk
  M. John Chapman, J. S. Redfern, Mark E. McGovern, Philippe Giral> ;Pharmacology & Therapeutics. 2010 Jun 1
• 1 citations
  Optimal management of persistent mixed dyslipidemia after statin initiation warrants combination therapy.
  William E. Boden, Mark E. McGovern> ;The American Journal of Cardiology. 2009 Dec 15
• 110 citations
  Comparative effects on lipid levels of combination therapy with a statin and extended-release niacin or ezetimibe versus a statin alone (the COMPELL study).
  James M. McKenney, Peter B. Jones, Harold E. Bays, Robert H. Knopp, Moti L. Kashyap, Gary E. Ruoff, Mark E. McGovern> ;Atherosclerosis. 2007 Jun 1
• 82 citations
  Benefits of niacin in patients with versus without the metabolic syndrome and healed myocardial infarction (from the Coronary Drug Project).
  Paul L. Canner, Curt D. Furberg, Mark E. McGovern> ;The American Journal of Cardiology. 2006 Feb 15
• 36 citations
  Safety and efficacy of extended-release niacin for the treatment of dyslipidaemia in patients with HIV infection: AIDS Clinical Trials Group Study A5148.
  Michael P. Dubé, Julia W. Wu, Judith A. Aberg, Mark A. Deeg, Beverly Alston-Smith, Mark E McGovern, Daniel Lee, Sharon L Shriver, Ana I Martinez, Martha Greenwald, Jam...> ;Antiviral Therapy. 2006 Nov 1
• 1 citations
  Time as a Variable With Niacin Extended‐Release/Lovastatin vs. Atorvastatin and Simvastatin
  Harold E. Bays, Mark E. McGovern> ;Preventive Cardiology. 2005 Sep 1
• 4 citations
  Taking aim at HDL-C. Raising levels to reduce cardiovascular risk.
  Mark E. McGovern> ;Postgraduate Medicine. 2005 Apr 1
• 153 citations
  Benefits of niacin by glycemic status in patients with healed myocardial infarction (from the Coronary Drug Project)
  Paul L. Canner, Curt D. Furberg, Michael L. Terrin, Mark E. McGovern> ;The American Journal of Cardiology. 2005 Jan 15
• 27 citations
  Differential effect of two nicotinic acid preparations on low-density lipoprotein subclass distribution in patients classified as low-density lipoprotein pattern A, B,...
  H. Robert Superko, Mark E. McGovern, Elaine Raul, Brenda Garrett> ;The American Journal of Cardiology. 2004 Sep 1
• 49 citations
  Efficacy of extended-release niacin with lovastatin for hypercholesterolemia: assessing all reasonable doses with innovative surface graph analysis.
  William Insull, Mark E. McGovern, Helmut G. Schrott, Paul D. Thompson, J. Robin Crouse, Franklin J. Zieve, John Corbelli> ;Archives of Internal Medicine. 2004 May 24
• 72 citations
  Once-daily niacin extended release/lovastatin combination tablet has more favorable effects on lipoprotein particle size and subclass distribution than atorvastatin an...
  Harold E. Bays, Mark E. McGovern, Laurie A. Kopin> ;Preventive Cardiology. 2003 Oct 1
• 108 citations
  Comparison of once-daily, niacin extended-release/lovastatin with standard doses of atorvastatin and simvastatin (the ADvicor Versus Other Cholesterol-Modulating Agent...
  Harold E. Bays, Carlos A. Dujovne, Mark E. McGovern, T.Eric White, Moti L. Kashyap, A.Gene Hutcheson, John R. Crouse> ;The American Journal of Cardiology. 2003 Mar 15
• 46 citations
  A dose-ranging study of a new, once-daily, dual-component drug product containing niacin extended-release and lovastatin.
  Donald B. Hunninghake, Mark E. McGovern, Michael Koren, Ronald Brazg, David Murdock, Stuart Weiss, Thomas A. Pearson> ;Clinical Cardiology. 2003 Mar 1
• 384 citations
  Efficacy, safety, and tolerability of once-daily niacin for the treatment of dyslipidemia associated with type 2 diabetes: results of the assessment of diabetes contro...
  Scott M. Grundy, Gloria Lena Vega, Mark E. McGovern, Brian R. Tulloch, David M. Kendall, David Fitz-Patrick, Om P. Ganda, Robert S. Rosenson, John B. Buse, David D. Ro...> ;Archives of Internal Medicine. 2002 Jul 22
• 168 citations
  Long-term safety and efficacy of a once-daily niacin/lovastatin formulation for patients with dyslipidemia.
  Moti L. Kashyap, Mark E. McGovern, Kathleen Berra, John R. Guyton, Peter O. Kwiterovich, Wayne L Harper, Phillip D Toth, Laurence K Favrot, Boris Kerzner, Stephen D. N...> ;The American Journal of Cardiology. 2002 Mar 15
• 349 citations
  Pravastatin limitation of atherosclerosis in the coronary arteries (PLAC I): Reduction in atherosclerosis progression and clinical events
  Bertram Pitt, G. B. J. Mancini, Stephen G. Ellis, Howard S Rosman, J.-S. Park, Mark E. McGovern> ;Journal of the American College of Cardiology. 1995 Nov 1
• Join now to see all